Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolebrutinib long-term extension in relapsing multiple sclerosis
NCT03996291Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2019
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of tolebrutinib in multiple sclerosis (MS), sponsored by Sanofi. Started Sep 2019; status: completed.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03996291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03996291.